Skip to main content
. 2021 Oct 18;8(23):2102414. doi: 10.1002/advs.202102414

Figure 6.

Figure 6

Therapeutic efficacy of LCB‐ADCs in HER2‐positive GC PDX models. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in an HER2 +++ GC PDX model. The drugs were i.v. injected at 5 mg kg−1 once (↑), n = 5. b) Effect of LCB‐ADC1, LCB‐ADC3, T‐DM1 in an HER2 ++ GC PDX model. Drugs were i.v. injected at 5 mg kg−1 twice (↑), n = 5. Data values are a mean ± standard deviation. **p < 0.01 (T‐DM1 vs LCB‐ADC3, single or repeated treatment). HER2 expression in tumor tissues was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c,d) Mice bearing HER2 ++ GC patient‐derived tumors were i.v. administered with LCB‐ADC1, LCB‐ADC3, or T‐DM1 at 5 mg kg−1, every other week for 4 weeks, n = 5. At the end of the experiment, c) tumors were isolated, photographed (scale bar, 1 cm) and d) weighed. Data values are mean ± standard deviation. *p < 0.05 (T‐DM1 vs LCB‐ADC1), **p < 0.01 (T‐DM1 vs LCB‐ADC3).